Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
Liver cancer survival rates reflect income disparities
2.
Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
More People Than Previously Believed Have Schizophrenia.
5.
Smoker's Painless Skin Nodules Flag a Fatal Diagnosis
1.
Evolutionary Bottlenecks in Tumor Progression
2.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
3.
Patient Management for Bone Marrow Functional Recovery Pathways
4.
Cancer Cachexia: Emerging Therapeutic Strategies
5.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation